GLP-1 receptor agonists (exenatide, liraglutide) and DPP-4 inhibitors (sitagliptin) represent major new diabetes drug classes, with weight loss benefits and low hypoglycemia risk distinguishing them from existing therapies.
Key findingNew diabetes drugs include GLP-1 agonists (exenatide, liraglutide: injectable, weight loss, low hypo risk), DPP-4 inhibitors (sitagliptin, vildaglipti
What the researchers found
New diabetes drugs include GLP-1 agonists (exenatide, liraglutide: injectable, weight loss, low hypo risk), DPP-4 inhibitors (sitagliptin, vildagliptin: oral, weight neutral), and amylin analog (pramlintide) — peptide-based drugs transforming type 2 diabetes treatment.
Why it matters
Relevant for glp-1, diabetes, semaglutide, tirzepatide.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
New drugs for type 2 diabetes mellitus: what is their place in therapy?
Drugs, 68(15), 2131-62
Citation
Krentz, Andrew J; Patel, Mayank B; Bailey, Clifford J. (2008). New drugs for type 2 diabetes mellitus: what is their place in therapy?. Drugs, 68(15), 2131-62.